The Cancer Genomics Shared Resource (CGSR) combines state-of-the-art genomic instrumentation with outstanding technical expertise. Members of the Winship Cancer Institute (Winship) benefit from services that facilitate basic science as well as translational research in a CLIA-certified environment. These services are delivered by experienced genomics professionals who ensure that all Instrumentation and procedures are rigorously quality controlled. Recent key equipment purchases underscore the CGSR's focus on new technologies and next generation sequencing for cancer research applications and include an llumina HiScan, Fluidigm Access Array, and lon Torrent Personal Genome Machine. The CSGR has been able to remain price-competitive for services through funding from the Cancer Center Support Grant (5% of annual operating costs) and Winship institutional support (30% of annual operating costs). In the past year, gene expression and methylation array data generated by the CGSR have contributed to high impact publications and successful multi-investigator grant awards including as NASA Specialized Center of Research (PI: Ya Wang, Ph.D.). With new leadership and well defined strategic initiatives, the CGSR is advancing its role in cancer diagnosis and disease classification, risk stratification, and therapeutic decision-making at the Winship Cancer Institute.

Public Health Relevance

The Winship Cancer Genomics Shared Resource allows cancer scientists to conduct sophisticated genome studies that would not otherwise be feasible in their own laboratories. The data generated by the use of this facility lead to a better understanding of the genetic basis of cancer in novel service to cancer treatment and prevention.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Emory University
United States
Zip Code
Bilen, Mehmet Asim; Dutcher, Giselle Marie Almeida; Liu, Yuan et al. (2018) Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab. Clin Genitourin Cancer 16:e563-e575
Chowdhary, Mudit; Switchenko, Jeffrey M; Press, Robert H et al. (2018) Post-treatment neutrophil-to-lymphocyte ratio predicts for overall survival in brain metastases treated with stereotactic radiosurgery. J Neurooncol 139:689-697
Morgan, T M; Wang, X; Qian, X et al. (2018) Measurement of circulating tumor cells in squamous cell carcinoma of the head and neck and patient outcomes. Clin Transl Oncol :
Lin, Songbai; Han, Yiran; Jenkin, Kayte et al. (2018) Lysophosphatidic Acid Receptor 1 Is Important for Intestinal Epithelial Barrier Function and Susceptibility to Colitis. Am J Pathol 188:353-366
Zhu, Dan; Osuka, Satoru; Zhang, Zhaobin et al. (2018) BAI1 Suppresses Medulloblastoma Formation by Protecting p53 from Mdm2-Mediated Degradation. Cancer Cell 33:1004-1016.e5
Bekhbat, Mandakh; Chu, Karen; Le, Ngoc-Anh et al. (2018) Glucose and lipid-related biomarkers and the antidepressant response to infliximab in patients with treatment-resistant depression. Psychoneuroendocrinology 98:222-229
Felger, Jennifer C; Haroon, Ebrahim; Patel, Trusharth A et al. (2018) What does plasma CRP tell us about peripheral and central inflammation in depression? Mol Psychiatry :
Akce, Mehmet; Zaidi, Mohammad Y; Waller, Edmund K et al. (2018) The Potential of CAR T Cell Therapy in Pancreatic Cancer. Front Immunol 9:2166
Greenwell, I Brian; Staton, Ashley D; Lee, Michael J et al. (2018) Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. Cancer 124:2306-2315
Hou, Yue; Konen, Jessica; Brat, Daniel J et al. (2018) TASI: A software tool for spatial-temporal quantification of tumor spheroid dynamics. Sci Rep 8:7248

Showing the most recent 10 out of 331 publications